Cytokinetics to Participate in Upcoming Investor Conferences
June 02, 2022 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2022 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2022 it granted stock options to purchase an aggregate of...
Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress
May 23, 2022 11:30 ET
|
Cytokinetics, Incorporated
Data from Up to Six Months of Treatment with Aficamten Show Significant and Sustained Reductions in LVOT Gradients with Improvements in Functional Class, Symptoms, and Biomarkers Analyses from...
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
May 18, 2022 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., AND WASHINGTON, May 18, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership...
Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference
May 17, 2022 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...
Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil
May 17, 2022 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the Company recently participated in a mid-cycle communication meeting with...
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress
May 16, 2022 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late-Breaking Science presentations at Heart Failure 2022, an...
Cytokinetics to Hold Annual Meeting of Stockholders
May 03, 2022 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Tuesday, May 10, 2022...
Cytokinetics to Announce First Quarter Results on May 4, 2022
April 20, 2022 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2022 at 4:00...
Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference
April 06, 2022 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...